Since the NCEP ATP II LDL-C goals were established in 2001, seven major clinical end point trials with statin therapy have been published. These trials have provided a greater rationale for lowering target LDL-C levels, and for more intensive LDL-C-lowering therapy. This slide show will discuss challenges and identify potential strategies for treating at-risk patients in need of lower LDL-C targets.